DXCM AI Stock Analysis – Buy, Hold, or Avoid?
DexCom, Inc. (DXCM)
Dexcom (DXCM) offers a compelling long-term growth story driven by industry leadership in continuous glucose monitoring, robust fundamentals, and strong sentiment, though short-term technicals suggest a neutral stance. The stock is fairly valued relative to its growth prospects, with analyst targets indicating double-digit upside. Risks are moderate and manageable, making DXCM a strong candidate for long-term investors and a potential buy on near-term pullbacks.
Fundamentals
Dexcom (DXCM) continues to deliver robust top-line and bottom-line growth, solidifying its position as a leader in continuous glucose monitoring (CGM). Recent results reflect both scale advantages and increasing profitability, supported by sustained market expansion. While valuation remains elevated, the business fundamentals and secular growth opportunities are strong.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
13.12% YoY
Q4 2025
Net Income
76.20% YoY
Q4 2025
Net Margin
Q4 2025
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q4 2025
Net Income Growth YoY
Latest Quarter: Q4 2025
Revenue Per Share Growth YoY
Latest Quarter: Q4 2025
EPS Growth YoY
Latest Quarter: Q4 2025
Book Value Per Share Growth YoY
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.3B | 1.2B | 1.2B | 1.0B | 1.1B | 994.2M | 1.0B | 921.0M |
| Revenue Growth YoY | +13.12% | +21.64% | +15.21% | +12.49% | +7.64% | +1.97% | +15.26% | +24.21% |
| Net Income | 267.3M | 283.8M | 179.8M | 105.4M | 151.7M | 134.6M | 143.5M | 146.4M |
| Net Income Growth YoY | +76.20% | +110.85% | +25.30% | -28.01% | -40.81% | +11.52% | +23.81% | +201.23% |
| EPS | $0.69 | $0.73 | $0.46 | $0.27 | $0.39 | $0.35 | $0.36 | $0.38 |
| EPS Growth YoY | +76.92% | +108.57% | +27.78% | -28.95% | -41.79% | +12.90% | +20.00% | +192.31% |
Profitability Metrics
Gross Margin
TTM
Operating Margin
TTM
Net Margin
TTM
Return on Equity
TTM
Return on Assets
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 62.93% | 60.48% | 59.53% | 56.85% | 58.90% | 59.73% | 62.40% | 61.01% |
| Operating Margin | 25.64% | 20.05% | 18.37% | 12.91% | 16.96% | 15.29% | 15.73% | 10.98% |
| Net Margin | 21.22% | 23.47% | 15.54% | 10.17% | 13.62% | 13.54% | 14.29% | 15.90% |
| Return on Equity (ROE) | 9.73% | 10.41% | 6.99% | 4.65% | 7.21% | 6.80% | 5.89% | 6.52% |
| Return on Assets (ROA) | 4.28% | 3.84% | 2.49% | 1.59% | 2.39% | 2.16% | 2.15% | 2.31% |
Technical Analysis
DXCM is currently trading near resistance levels around $73.44 with support near $70.07, showing a neutral to slightly bullish technical setup as momentum oscillators are mixed but moving averages are predominantly bullish. The stock is consolidating with reduced volatility, and technical signals indicate a cautious stance with potential for a breakout above resistance. MACD and RSI indicators currently reflect neutral to mild buying pressure, with moving averages supporting an overall bullish bias.
No extreme reading
Mixed signals
Range-bound market
Watching for cross
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Dexcom (DXCM) continues to deliver robust top-line and bottom-line growth, solidifying its position as a leader in continuous glucose monitoring (CGM). Recent results reflect both scale advantages and increasing profitability, supported by sustained market expansion. While valuation remains elevated, the business fundamentals and secular growth opportunities are strong.
Latest Earnings
Q4 2025 Earnings (Dec 30, 2025)
Earnings Per Share (EPS)
Actual
$0.68
Estimated
$0.65
Surprise
+$0.03
Surprise %
+4.62%
Revenue
Actual
$1.26B
Estimated
$1.18B
Surprise
+$76.67M
Surprise %
+6.48%
Historical Earnings
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $0.68 | $0.61 | $0.48 | $0.32 | $0.45 | $0.45 | $0.43 | $0.32 |
| EPS (Estimated) | $0.65 | $0.58 | $0.44 | $0.33 | $0.48 | $0.44 | $0.39 | $0.27 |
| EPS Surprise | +$0.03 | +$0.03 | +$0.04 | -$0.01 | -$0.03 | +$0.01 | +$0.04 | +$0.05 |
| % Diff | +4.6% | +5.9% | +8.2% | -2.2% | -6.1% | +2.3% | +10.3% | +18.5% |
| Revenue | ||||||||
| Revenue (Actual) | $1.26B | $1.21B | $1.16B | $1.04B | $1.11B | $994.2M | $1B | $921M |
| Revenue (Estimated) | $1.18B | $1.18B | $1.12B | $1.02B | $1.11B | $990.44M | $1.04B | $909.93M |
| Revenue Surprise | +$76.67M | +$25.56M | +$32.49M | +$18.59M | +$4.35M | +$3.76M | -$32.9M | +$11.07M |
| % Diff | +6.5% | +2.2% | +2.9% | +1.8% | +0.4% | +0.4% | -3.2% | +1.2% |
Valuation
DexCom (DXCM) currently trades at a premium valuation compared to its medical equipment peers and sector averages, reflecting strong investor confidence in its robust growth and profitability metrics. Despite elevated multiples, analyst consensus suggests undervaluation with upside potential toward an $85 price target driven by solid revenue growth and improving earnings. Technical indicators also imply recent oversold conditions that may support near-term price appreciation.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 24.00 | 23.18 | 47.59 | 63.35 | 51.18 | 49.08 | 78.01 | 91.91 |
| Price to Sales | 20.38 | 21.76 | 29.58 | 25.78 | 27.89 | 26.58 | 44.59 | 58.44 |
| Price to Book | 9.35 | 9.65 | 13.30 | 11.78 | 14.77 | 13.35 | 18.39 | 23.96 |
| Enterprise Value to EBITDA | 67.33 | 64.33 | 115.44 | 129.62 | 120.57 | 119.62 | 189.76 | 293.05 |
| Enterprise Value to Revenue | 20.75 | 22.37 | 30.81 | 27.40 | 29.67 | 28.56 | 46.23 | 60.33 |
Sentiment & Analyst Ratings
DexCom (DXCM) exhibits predominantly positive market sentiment supported by strong analyst buy ratings and optimistic price targets around $85. The company’s recent developments, including leadership changes and product launches, reinforce confidence despite supply chain challenges. Social media sentiment mirrors general optimism with retail investors focusing on growth potential while technical indicators suggest the stock is currently oversold, indicating a possible near-term rebound.
Analyst Recommendations
Risk Assessment
Dexcom (DXCM) presents a moderate risk profile backed by improving liquidity and reduced leverage compared to prior periods. The company operates in a competitive and regulated medical device sector, with significant growth opportunities in diabetes monitoring and expansion in type 2 diabetes markets, offset partially by regulatory and competitive risks.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q4 2025
Quick Ratio
Latest Quarter: Q4 2025
Debt-to-Equity
Latest Quarter: Q4 2025
Debt-to-Assets
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 1.88 | 1.56 | 1.52 | 1.50 | 1.47 | 2.46 | 2.82 | 2.90 |
| Quick Ratio | 1.59 | 1.38 | 1.35 | 1.32 | 1.28 | 2.12 | 2.48 | 2.53 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 0.51 | 0.94 | 1.00 | 1.14 | 1.23 | 1.31 | 1.07 | 1.15 |
| Debt-to-Assets | 0.22 | 0.34 | 0.35 | 0.38 | 0.40 | 0.41 | 0.38 | 0.40 |
Liquidity Assessment
Current Ratio: 1.88(Strong)
Quick Ratio: 1.59(Strong)
The company has strong liquidity with sufficient short-term assets to cover liabilities.
Solvency Assessment
Debt-to-Equity: 0.51(Moderate)
Debt-to-Assets: 0.22(Low)
The company maintains a balanced capital structure with manageable debt levels.
Frequently Asked Questions about DXCM
AI Answers: Common Questions About DXCM
Get AI-powered answers to the questions investors ask most about DexCom, Inc.
DXCM is a good buy for medium- and long-term investors, trading at $73.26 with a P/E of 35.05 and analyst targets around $85 (17% upside). Its premium valuation is justified by 15.6% revenue growth, 45% net income growth, and expanding margins, though short-term traders may want to wait for a technical breakout.
Unless your thesis has changed or you need to reduce risk, there is no strong reason to sell now; fundamentals are strong, sentiment is positive, and technicals are not bearish, though short-term consolidation could mean better entry points for new capital.
The biggest risks are regulatory or Medicare reimbursement changes, rising competition (notably from Abbott and Medtronic), and supply chain or quality issues. Debt and liquidity metrics are healthy (current ratio 1.88, debt/equity 0.51), so financial risk is moderate.
Analyst consensus targets are around $85.85, with technical resistance at $74.38 and support at $70.07. This implies 15-17% upside from current levels, with a breakout above $74.38 likely to trigger further gains.
DXCM is fairly valued at a P/E of 35.05 and high EV/EBITDA, above sector averages but justified by superior growth and profitability. Forward multiples have contracted from historical highs, and ongoing earnings growth supports the current premium.
Fundamentals are very strong: revenue up 15.6% YoY, net income up 45%, gross margin above 60%, net margin at 18%, and improving liquidity and leverage. Growth is organic and recurring, with high-quality earnings and robust cash flow.
Technical analysis is neutral: the stock is consolidating near resistance ($73.44-$74.38) with support at $70.07, RSI is mixed (28-62), and moving averages are bullish. Wait for a breakout above $74 or buy on dips near support for best risk/reward.
Key catalysts include upcoming earnings releases, new product launches (G7, G8, Stelo), continued international expansion, and positive news on reimbursement or digital health integration. Watch for technical breakouts and volume spikes as confirmation.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.